Capsule Fluoxetine 20mg
|Generic Name of Product||Brand Name||Dosage Form||Strength||Pharmacologic Group||Therapeutic Group||Unit Per Pack|
|Fluoxetine||Lorazac®||Capsule||20 mg||Selective serotonin reuptake inhibitor||Nervous system||100|
Indications And Usage
Lorazac and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder
Major Depressive Disorder:
Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose.
Pediatric: Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose should be increased to 20 mg/day.
Obsessive Compulsive Disorder:
Adult: A dose of 20 mg/day, administered in the morning, is recommended as the initial dose. The full therapeutic effect may be delayed until 5 weeks of treatment or longer.
Pediatric: In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose should be increased to 20 mg/day. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg.
The recommended dose is 60 mg/day, administered in the morning.
Treatment should be initiated with a dose of 10 mg/day. After one week, the dose should be increased to 20 mg/day.
Monoamine Oxidase Inhibitors, Pimozide, Thioridazine
Clinical Worsening and Suicide Risk, Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like Reactions, Allergic Reactions and Rash, Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania, Seizures, Altered Appetite and Weight, Abnormal Bleeding, Hyponatremia, Anxiety and Insomnia, Use in Patients With Concomitant Illness, Potential for Cognitive and Motor Impairment, Long Elimination Half-Life, Discontinuation of Treatment, Lorazac and Olanzapine in Combination
More common: Hives, itching, or skin rash, inability to sit still, restlessness
Less common: Chills or fever, joint or muscle pain
Pregnancy and lactation
Renal and liver Impairment
Renal impairment: Use caution; drug accumulation may occur with severe renal impairment
Hepatic impairment (cirrhosis): Decreased clearance of parent drug and active metabolite (norfluoxetine); lower or less frequent dose recommended
|There are no specific laboratory tests recommended.|